Oxidative Stress Biomarker for Nausea Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict and control chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV), as nausea is a subjective experience and poorly understood, leading to underestimation of risk and inadequate management.
Innovation Solution
A method to predict nausea by assessing oxidative stress levels in a mammalian subject's bloodstream before administering emetogenic agents, using glutathione (GSH) recycling dependent antioxidant activity as an indicator, to optimize antiemetic drug regimens and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional risk assessment tools based on patient demographics (age, gender) are used, then the assessment process is simple, but the prediction accuracy of CINV risk is insufficient
Solution Approach 1:
The patent introduces oxidative stress level as an intermediary biomarker that mediates between the simple demographic assessment and the complex physiological response to chemotherapy. By measuring oxidative stress in blood samples, the system provides an objective intermediate indicator that improves prediction accuracy without requiring direct measurement of the complex nausea response.
Solution Approach 2:
The patent replaces the subjective mechanical assessment (patient self-reporting and demographic-based estimation) with an objective biochemical measurement system. By substituting the mechanical/subjective assessment method with a biochemical assay measuring oxidative stress markers, the system achieves higher precision while maintaining practical simplicity.
2Reliability
If standardized antiemetic regimens are administered to all patients, then the treatment protocol is simple, but the effectiveness in preventing nausea is insufficient
Solution Approach 1:
The patent applies preliminary action by measuring oxidative stress levels before chemotherapy administration and using this pre-assessment to determine the appropriate antiemetic regimen. This preliminary biochemical characterization allows the treatment protocol to be optimized in advance for each patient, improving effectiveness while keeping the actual treatment administration straightforward.
Solution Approach 2:
The patent applies local quality by tailoring the antiemetic treatment to each patient's specific oxidative stress profile rather than applying a uniform regimen. Patients with high oxidative stress receive more intensive antiemetic prophylaxis, while those with low oxidative stress receive standard or reduced treatment, optimizing effectiveness for each local case.
3Reliability
If oxidative stress assessment is implemented to personalize treatment, then treatment effectiveness improves, but the cost and complexity of assessment increase
Solution Approach 1:
The patent extracts the key predictive information (oxidative stress level) from a simple blood sample and uses this extracted biomarker to guide treatment decisions. By taking out only the essential oxidative stress measurement rather than performing comprehensive physiological assessments, the system achieves personalization while minimizing resource consumption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized antiemetic treatment plans, effectively reducing the incidence of moderate to severe nausea by tailoring drug regimens based on individual oxidative stress levels, improving patient outcomes and treatment experiences.
Implementation Method 1
assaying a biological sample containing red blood cells for a level of oxidative stress
Implementation Method 2
assessing the glutathione (GSH) recycling dependent antioxidant activity of the RBC in the sample
Data Source
AI summary
A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent. e.g., a cytostatic agent or a surgical anesthetic.